Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

• Status: Unknown status
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Deutsches Herzzentrum Muenchen
• Collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
• Treatments: Prasugrel Hydrochloride; Ticagrelor

Criteria

Major Inclusion Criteria:

Hospitalization for an acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction or unstable angina pectoris) with planned invasive strategy

Major Exclusion Criteria:

1. intolerance of or allergy to ticagrelor or prasugrel

2. history of any stroke, transient ischemic attack or intracranial bleeding

3. known intracranial neoplasm, intracranial arteriovenous malformation or intracranial aneurysm

4. active bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding

5. fibrin-specific fibrinolytic therapy less than 24 h before randomization, non-fibrin-specific fibrinolytic therapy less than 48 h before randomization

6. known platelet count < 100.000/μL at the time of screening

7. known anemia (hemoglobin <10 g/dL) at the time of screening

8. oral anticoagulation that cannot be safely discontinued for the duration of the study

9. INR known to be greater than 1.5 at the time of screening

10. chronic renal insufficiency requiring dialysis

11. moderate or severe hepatic dysfunction (Child Pugh B or C)

12. increased risk of bradycardia events (Sick Sinus, AV block grade II or III, bradycardia-induced syncope)

13. index event is an acute complication (< 30 days) of PCI

14. concomitant medical illness that in the opinion of the investigator is associated with a life expectancy < 1 year

15. concomitant oral or i.v. therapy with strong CYP3A Inhibitors (e.g. ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d), CYP3A substrates with narrow therapeutic indices (e.g. cyclosporine, quinidine), or strong CYP3A inducers (e.g. rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital ) that cannot be safely discontinued

16. ≥1 doses of ticagrelor or prasugrel within 5 days before randomisation

17. no written informed consent

18. participation in another investigational drug study

19. previous enrolment in this study

20. for women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study

21. Pregnancy, giving birth within the last 90 days, or lactation

22. inability to cooperate with protocol requirements